… randomized phase II trial to evaluate two treatment strategies in the first-line management of
advanced non–small-cell lung cancer (NSCLC) patients with a performance status (PS) of 2. …

Purpose To compare single-agent pemetrexed (P) versus the combination of carboplatin and
pemetrexed (CP) in first-line therapy for patients with advanced non–small-cell lung cancer …

… An estimated 30% to 40% of patients with advanced non–small-cell lung cancer (NSCLC)
have a poor performance status (PS). PS is an independent prognostic factor for survival 2 ; …

… On these bases, in 2008, we started a randomized phase 3 trial (CAPPA-2, Cisplatin Added
to Gemcitabine in Poor Performance Advanced NSCLC patients – PS2) to assess whether …

A prospective randomized study was conducted to determine whether amifostine (Ethyol)
reduces the rate of severe esophagitis and hematologic and pulmonary toxicity associated with …

… We conducted a multicenter randomized phase II trial to evaluate two schedules of single-agent
docetaxel in the first-line treatment of elderly and performance status (PS) 2 patients with …

… .2, 5, 6 However, in a large phase 3 trial designed specifically for elderly patients, single-…
elderly and poor performance status patients, we performed a randomized phase 3 study that …

Purpose Appropriate therapy for Eastern Cooperative Oncology Group (ECOG) performance
status (PS)-2 patients with advanced non–small-cell lung cancer (NSCLC) remains …

… This randomized phase II study compared two treatment schedules of gemcitabine in patients
with non–small-cell lung cancer (NSCLC) and impaired Karnofsky performance status (KP)…

… was most marked in patients with performance status 3. … chemotherapy to patients with good
performance status (PS), … An important randomized study in elderly NSCLC patients done …